ClinicalTrials.gg
TerminatedNCT05284019EVECUpdated May 29, 2024Results posted

Real World Effectiveness of Eptinezumab in Participants With Migraine

A Phase 4 interventional study of Eptinezumab and Erenumab in Migraine, sponsored by H. Lundbeck A/S. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated due to enrolment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
20th of 21
32 · median 193
Started
2022
with 1 other
Phase 4
4 of 21
1 open now
Registered
15th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 20th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 15th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of migraine per International Headache Society (IHS) International Classification of Headache Disorder (ICHD)-3 guidelines at least 12 months prior to screening.
  • Have a history of ≥ 8 migraine days/month in 2 of the previous 3 months as confirmed by the treating physician through medical records.
  • Be able to understand the clinical description of treatment options and have the capability to participate fully in making their treatment preferences known.
  • Be willing to accept randomization to any of the possible study medications if allocated to that treatment arm.
  • Be willing and capable of completing daily reports and other participant reported outcome measures using a smartphone-based application.

Exclusion criteria

Exclusion Criteria:

  • The participant has a history of severe drug allergy or , or known hypersensitivity or intolerance to either eptinezumab, erenumab, fremanezumab, galcanezumab or their .
  • The participant has previous history of use of any of the study drugs (for example, eptinezumab, Botox, erenumab, fremanezumab or galcanezumab). Note that only previous Botox use for treatment of migraine is exclusionary. Prior use of Botox for cosmetic purposes is allowed.
  • The participant has a diagnosis of CM and has hypersensitivity to botulinum toxin preparation or to any of the components in the formulation.
  • The participant has used opioids or butalbital-containing products greater than 4 days per month in the last month.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.

    Drug: Eptinezumab

  • Experimental
    Anti-CGRP injectables

    Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.

    Drug: Erenumab · Drug: Fremanezumab · Drug: Galcanezumab

  • Experimental
    Onabotulinumtoxin-A

    Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.

    Drug: Onabotulinumtoxin-A

Interventions

  • Concentrate for solution for IV infusion

    Also known as: Vyepti

  • Solution for SC Injection

    Also known as: Aimovig®

  • Solution for IM Injection

  • Solution for SC Injection

    Also known as: Ajovy®

  • Solution for SC Injection

    Also known as: Emgality®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Patient-informed Most Bothersome Symptom (PI-MBS) Score at Week 24

    Participants select the symptom that they find most impairs them at the time of reporting and rate the severity of that symptom on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

    Time frame: Baseline, Week 24

  2. Number of "Good Days" From Baseline

    The participants report the number of "good days" and "bad days" they had in the previous week on a weekly basis using the good day/bad day scale.

    Time frame: Up to Week 24

  3. Change From Baseline in Quality of Life (QOL) as Measured by the 5 Level Euro Quality of Life 5 Dimensional Questionnaire (EQ-5D-5L) Score at Week 24

    The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analog scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Week 24

  4. Health Care Resources Utilization (HCRU): Number of Participants Who Used Health Services and Medications

    Time frame: Up to Week 24

  5. QOL as Measured by the 6 Item Headache Impact Test (HIT-6) Score

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item is rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 is the sum of each response score ranging from 36 to 78. The life impact derived from the total score is described as follows: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Up to Week 24

  6. QOL as Measured by the Migraine Disability Assessment (MIDAS) Total Score

    The Midas score is a participant completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability.

    Time frame: Up to Week 24

  7. Participant Satisfaction Score as Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

    The TSQM assesses four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction).

    Time frame: Week 24

  8. Percentage of Participants That Switch From the Preventive Medication They Are Randomized to at Baseline to Another Preventive Medication

    Time frame: Week 24

07

Results

Posted May 29, 2024
Limitations and caveats
The study was terminated early due to enrolment challenges.

Participant flow

Participant flow — Overall Study
MilestoneErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumab
Started322817
Received at least 1 dose of study drug322816
Completed00000
Not completed322817
Withdrew: Study terminated222515
Withdrew: Withdrawal by subject00011
Withdrew: Lost to follow-up10021

Outcome measures

PrimaryChange From Baseline in Patient-informed Most Bothersome Symptom (PI-MBS) Score at Week 24

Participants select the symptom that they find most impairs them at the time of reporting and rate the severity of that symptom on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

PrimaryNumber of "Good Days" From Baseline

The participants report the number of "good days" and "bad days" they had in the previous week on a weekly basis using the good day/bad day scale.

Time frame:
Up to Week 24

No measurements were reported for this outcome.

PrimaryChange From Baseline in Quality of Life (QOL) as Measured by the 5 Level Euro Quality of Life 5 Dimensional Questionnaire (EQ-5D-5L) Score at Week 24

The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analog scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

PrimaryHealth Care Resources Utilization (HCRU): Number of Participants Who Used Health Services and Medications
Time frame:
Up to Week 24

No measurements were reported for this outcome.

PrimaryQOL as Measured by the 6 Item Headache Impact Test (HIT-6) Score

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item is rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 is the sum of each response score ranging from 36 to 78. The life impact derived from the total score is described as follows: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Up to Week 24

No measurements were reported for this outcome.

PrimaryQOL as Measured by the Migraine Disability Assessment (MIDAS) Total Score

The Midas score is a participant completed 5-item questionnaire about lost time and productivity (for work, school or family/social activities) in the past 3 months (number of days missed) where: 0-5=Little or No disability, 6-10=Mild disability, 11-20=Moderate disability or 21+ Severe disability.

Time frame:
Up to Week 24

No measurements were reported for this outcome.

PrimaryParticipant Satisfaction Score as Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

The TSQM assesses four domains of participants' satisfaction with treatment, with scale ranges from 0 (extremely dissatisfied) to 100 (not at all dissatisfied) for each of the categories (Effectiveness, Side Effects, Convenience, and Overall Satisfaction).

Time frame:
Week 24

No measurements were reported for this outcome.

PrimaryPercentage of Participants That Switch From the Preventive Medication They Are Randomized to at Baseline to Another Preventive Medication
Time frame:
Week 24

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Erenumab0/3 (0%)0/3 (0%)0/3 (0%)
Fremanezumab0/2 (0%)0/2 (0%)0/2 (0%)
Onabotulinumtoxin-A0/2 (0%)0/2 (0%)0/2 (0%)
Galcanezumab0/8 (0%)0/8 (0%)6/8 (75%)
Eptinezumab0/16 (0%)0/16 (0%)4/16 (25%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumab
SinusitisInfections and infestations0/30/20/22/80/16
COVID-19Infections and infestations0/30/20/21/80/16
Upper respiratory tract infectionInfections and infestations0/30/20/21/81/16
Urinary tract infectionInfections and infestations0/30/20/21/81/16
MigraineNervous system disorders0/30/20/21/80/16
Attention deficit hyperactivity disorderPsychiatric disorders0/30/20/21/80/16
Gastric ulcerGastrointestinal disorders0/30/20/20/81/16
Pelvic floor dysfunctionGastrointestinal disorders0/30/20/20/81/16
Facial painGeneral disorders0/30/20/20/81/16
Swelling faceGeneral disorders0/30/20/20/81/16

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)ErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumabTotal
Mean47.3 ± 6.460.5 ± 4.930.5 ± 17.743.1 ± 12.638.2 ± 10.541.2 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)ErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumabTotal
Female32261528
Male000224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumabTotal
Hispanic or Latino210159
Not Hispanic or Latino11271223
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ErenumabFremanezumabOnabotulinumtoxin-AGalcanezumabEptinezumabTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American0114410
White31141221
More than one race000000
Unknown or Not Reported000011
08

Study locations

10 sites
  • Gilbert Neurology Partners/ CCT Research
    Gilbert, Arizona 85297, United States
  • Ki Clinical Research LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Innovation Medical Group
    Palmetto Bay, Florida 33157, United States
  • The Headache Center
    Ridgeland, Mississippi 39157, United States
  • North Kansas City Hospital
    North Kansas City, Missouri 64416, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Dent Neurologic Institute - Amherst
    Amherst, New York 14226, United States
  • Carolina Women's Research and Wellness Center
    Durham, North Carolina 27713, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Olympus Family Medicine/CCT Research
    Salt Lake City, Utah 84117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Feb 2023, 11 months.

Results were first posted in May 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 17, 2022
StartActual
Mar 4, 2022
Primary completionActual
Feb 17, 2023
CompletionActual
Apr 14, 2023
Results first posted
May 29, 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05284019
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Mar 4, 2022
Primary completion
Feb 17, 2023
Completion
Apr 14, 2023
Results posted
May 29, 2024
Last update
May 29, 2024

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eptinezumab · Erenumab · Onabotulinum toxin A · Fremanezumab · Galcanezumab

Start the discussion